Review



human anti leptin neutralizing mab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems human anti leptin neutralizing mab
    Human Anti Leptin Neutralizing Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti leptin neutralizing mab/product/R&D Systems
    Average 93 stars, based on 15 article reviews
    human anti leptin neutralizing mab - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    93
    R&D Systems human anti leptin neutralizing mab
    Human Anti Leptin Neutralizing Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti leptin neutralizing mab/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human anti leptin neutralizing mab - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    R&D Systems anti human leptin neutralization mab
    Figure 1. Effects of <t>leptin</t> on viability on eosinophils. Eosinophils (5 105/well) were cultured with or without leptin (50 ng/mL) for 24 h in a 24-well plate. Apoptosis of eosinophils was assessed by the TACSTM Annexin V-FITC assay using flow cytometry. Representative dot plots of (A) medium control (CTL), and (B) leptin-treated eosinophils were shown from triplicate experiments.
    Anti Human Leptin Neutralization Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human leptin neutralization mab/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    anti human leptin neutralization mab - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. Effects of leptin on viability on eosinophils. Eosinophils (5 105/well) were cultured with or without leptin (50 ng/mL) for 24 h in a 24-well plate. Apoptosis of eosinophils was assessed by the TACSTM Annexin V-FITC assay using flow cytometry. Representative dot plots of (A) medium control (CTL), and (B) leptin-treated eosinophils were shown from triplicate experiments.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 1. Effects of leptin on viability on eosinophils. Eosinophils (5 105/well) were cultured with or without leptin (50 ng/mL) for 24 h in a 24-well plate. Apoptosis of eosinophils was assessed by the TACSTM Annexin V-FITC assay using flow cytometry. Representative dot plots of (A) medium control (CTL), and (B) leptin-treated eosinophils were shown from triplicate experiments.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Cell Culture, Flow Cytometry, Control

    Figure 2. Effects of leptin on cell surface expression of ICAM-1, CD18, ICAM-3 and L-selectin on eosinophils. Eosinophils (5 105/well) were cultured with leptin (0–100 ng/mL) for 16 h in a 24-well plate. Surface expression of adhesion molecules per 10 000 viable cells was analyzed by flow cytometry as MFI; (A) representative histograms of the changes in the expression of adhesion molecules. Results of (B) ICAM-1, (C) CD18, (D) ICAM-3 and (E) L-selectin have been normalized by subtracting appropriate isotypic control and are expressed as the arithmetic mean SD of five independent experiments. * p<0.05, ** p<0.01 and *** p<0.001 when compared with medium control.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 2. Effects of leptin on cell surface expression of ICAM-1, CD18, ICAM-3 and L-selectin on eosinophils. Eosinophils (5 105/well) were cultured with leptin (0–100 ng/mL) for 16 h in a 24-well plate. Surface expression of adhesion molecules per 10 000 viable cells was analyzed by flow cytometry as MFI; (A) representative histograms of the changes in the expression of adhesion molecules. Results of (B) ICAM-1, (C) CD18, (D) ICAM-3 and (E) L-selectin have been normalized by subtracting appropriate isotypic control and are expressed as the arithmetic mean SD of five independent experiments. * p<0.05, ** p<0.01 and *** p<0.001 when compared with medium control.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Expressing, Cell Culture, Flow Cytometry, Control

    Fig. 10 shows that leptin-induced release of IL-1b and IL-6, and IL-8, GRO-a and MCP-1 was suppressed by BAY11–7082 and SB203580, and BAY11–7082, PD98059 and SB203580, respectively (all p<0.05).

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Fig. 10 shows that leptin-induced release of IL-1b and IL-6, and IL-8, GRO-a and MCP-1 was suppressed by BAY11–7082 and SB203580, and BAY11–7082, PD98059 and SB203580, respectively (all p<0.05).

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques:

    Figure 4. Effects of neutralization antibody against leptin on the biological activities of leptin on eosinophils. Leptin was incubated with or without neutralization antibody (0.1–10 lg/mL) for 15 min and then incubated with eosinophils (5 105/well) for the assay of (A) apoptosis, (B) cell surface of adhesion molecules, (C) chemokinesis and (D) induction of cytokines. Results were expressed as arithmetic mean plus SD from triplicate experiments. Mouse IgG1 was used as a nonspecific antibody for isotypic antibody control. # p<0.05; ## p<0.01 when compared with medium control (CTL); * p<0.05, ** p<0.01, *** p<0.001 when compared with leptin control (lep). Ab0.1: neutralization antibody (0.1 lg/mL); Ab1: neutralization antibody (1 lg/mL); Ab10: neutralization antibody (10 lg/mL); mIgG: mouse IgG1 (10 lg/mL).

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 4. Effects of neutralization antibody against leptin on the biological activities of leptin on eosinophils. Leptin was incubated with or without neutralization antibody (0.1–10 lg/mL) for 15 min and then incubated with eosinophils (5 105/well) for the assay of (A) apoptosis, (B) cell surface of adhesion molecules, (C) chemokinesis and (D) induction of cytokines. Results were expressed as arithmetic mean plus SD from triplicate experiments. Mouse IgG1 was used as a nonspecific antibody for isotypic antibody control. # p<0.05; ## p<0.01 when compared with medium control (CTL); * p<0.05, ** p<0.01, *** p<0.001 when compared with leptin control (lep). Ab0.1: neutralization antibody (0.1 lg/mL); Ab1: neutralization antibody (1 lg/mL); Ab10: neutralization antibody (10 lg/mL); mIgG: mouse IgG1 (10 lg/mL).

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Neutralization, Incubation, Control

    Figure 5. Representative expression profiles of intracellular phosphorylation of MAPK and other serine/threonine kinases of eosinophils upon activation by leptin. Eosinophils (1 107/ well) were treated with or without leptin (50 ng/mL) for 15 min. Eosinophils were then washed and lysed. Twenty-one different intracellular phosphorylated MAPK and other serine/threonine kinases in total cellular lysate were assessed semi-quantita- tively using an antibody based Human Phospho-MAPK Array Kit. Positive and negative controls were designated at (A1, A2, A21, A22, F1, F2) and (E3–E14), respectively. Triplicate experi- ments were performed with essentially identical results. The format of the antibodies on the array are detailed in Table 2.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 5. Representative expression profiles of intracellular phosphorylation of MAPK and other serine/threonine kinases of eosinophils upon activation by leptin. Eosinophils (1 107/ well) were treated with or without leptin (50 ng/mL) for 15 min. Eosinophils were then washed and lysed. Twenty-one different intracellular phosphorylated MAPK and other serine/threonine kinases in total cellular lysate were assessed semi-quantita- tively using an antibody based Human Phospho-MAPK Array Kit. Positive and negative controls were designated at (A1, A2, A21, A22, F1, F2) and (E3–E14), respectively. Triplicate experi- ments were performed with essentially identical results. The format of the antibodies on the array are detailed in Table 2.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Expressing, Phospho-proteomics, Activation Assay

    Figure 6. Activation of ERK, p38 MAPK, JAK2 and NF-jB activities in eosinophils by leptin. Eosinophils (1 107/well) were cultured with or without leptin (50 ng/mL) for different indicated incubation times. Total cellular proteins were extracted from eosinophils for the measurement of (A) phosphorylated and total p38 MAPK, (B) phosphorylated and total ERK, (C) phosphorylated and total IjBa, and (D) phosphorylated and total JAK2 by Western blot analysis. Experiments were performed in three independent replicates with essentially identical results, and representative results are shown.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 6. Activation of ERK, p38 MAPK, JAK2 and NF-jB activities in eosinophils by leptin. Eosinophils (1 107/well) were cultured with or without leptin (50 ng/mL) for different indicated incubation times. Total cellular proteins were extracted from eosinophils for the measurement of (A) phosphorylated and total p38 MAPK, (B) phosphorylated and total ERK, (C) phosphorylated and total IjBa, and (D) phosphorylated and total JAK2 by Western blot analysis. Experiments were performed in three independent replicates with essentially identical results, and representative results are shown.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Activation Assay, Cell Culture, Incubation, Western Blot

    Figure 7. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on viability of leptin-treated eosino- phils. Eosinophils (5 105/well) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for 24 h in a 24- well plate. Apoptosis of eosinophils was assessed by the TACSTM Annexin V-FITC assay using flow cytometry. Results were expressed as arithmetic mean plus SD from triplicate experiments. ## p<0.01 when compared with medium control; * p<0.05 when compared with the leptin control. AG: AG490; BAY: BAY11–7082; PD: PD98059; LY: LY294002; SB: SB203580; SP: SP600125; DM: DMSO-

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 7. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on viability of leptin-treated eosino- phils. Eosinophils (5 105/well) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for 24 h in a 24- well plate. Apoptosis of eosinophils was assessed by the TACSTM Annexin V-FITC assay using flow cytometry. Results were expressed as arithmetic mean plus SD from triplicate experiments. ## p<0.01 when compared with medium control; * p<0.05 when compared with the leptin control. AG: AG490; BAY: BAY11–7082; PD: PD98059; LY: LY294002; SB: SB203580; SP: SP600125; DM: DMSO-

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Incubation, Flow Cytometry, Control

    Figure 8. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on leptin-induced cell surface expression of (A) ICAM-1, (B) ICAM-3, (C) CD18, and (D) L-selectin on eosinophils. Eosinophils (5 105/well) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for further 16 h. Surface expression of the adhesion molecules of 10 000 cells was assessed by flow cytometry as MFI. Results are expressed as the arithmetic mean plus SD from five independent experiments. DMSO (0.1%) was used as the DMSO control. ### p<0.001 when compared with medium control; * p<0.05, ** p<0.01 when compared with the leptin control.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 8. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on leptin-induced cell surface expression of (A) ICAM-1, (B) ICAM-3, (C) CD18, and (D) L-selectin on eosinophils. Eosinophils (5 105/well) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for further 16 h. Surface expression of the adhesion molecules of 10 000 cells was assessed by flow cytometry as MFI. Results are expressed as the arithmetic mean plus SD from five independent experiments. DMSO (0.1%) was used as the DMSO control. ### p<0.001 when compared with medium control; * p<0.05, ** p<0.01 when compared with the leptin control.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Expressing, Incubation, Flow Cytometry, Control

    Figure 9. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on the migration of eosinophils induced by leptin. Eosinophils (5 104 cells) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for further 16 h. Eosinophils were then incubated in a 48-well microchamber in the upper chambers, while the RPMI medium was placed in the lower chambers. Migration was carried out for 6 h. Results are expressed as cell number/high power field with arithmetic mean plus SD of three independent experi- ments. # p<0.05 when compared with medium control; * p<0.05 when compared with the leptin control.

    Journal: European journal of immunology

    Article Title: Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation.

    doi: 10.1002/eji.200636866

    Figure Lengend Snippet: Figure 9. Effects of AG490, BAY11–7082, LY294002, PD98059, SB203580 and SP600125 on the migration of eosinophils induced by leptin. Eosinophils (5 104 cells) were pretreated with AG490 (10 lM), BAY11–7082 (1 lM), PD98059 (10 lM), LY294002 (5 lM), SB203580 (7.5 lM) or SP600125 (3 lM) for 1 h followed by incubation with or without leptin (50 ng/mL) for further 16 h. Eosinophils were then incubated in a 48-well microchamber in the upper chambers, while the RPMI medium was placed in the lower chambers. Migration was carried out for 6 h. Results are expressed as cell number/high power field with arithmetic mean plus SD of three independent experi- ments. # p<0.05 when compared with medium control; * p<0.05 when compared with the leptin control.

    Article Snippet: Anti-human leptin neutralization mAb was from R&D Systems (MN, USA) and mouse IgG1 antibody was from BD PharMingen (CA, USA).

    Techniques: Migration, Incubation, Control